Consultation
Dr. Carmona reviews your history, prior treatments, and confirms Spravato eligibility.
Spravato Treatment in Pembroke Pines, FL
A New Path to Mental Clarity
FDA Approval:Treatment-resistant depression + MDD with acute suicidal ideation
Administration:Nasal spray in certified REMS clinic
Monitoring:2-hour post-dose observation required
Session Frequency:Twice weekly initially, then tapered
Understanding
When Standard Antidepressants Fall Short of Spravato
A Different Mechanism of Action
Roughly one in three adults with major depressive disorder does not respond to two or more traditional oral antidepressants. If that describes you, you may feel exhausted, hopeless, or stuck in a cycle of trial-and-error prescriptions that never fully lift the heaviness. Many patients we see have tried SSRIs, SNRIs, atypicals, and augmentation strategies for months or years. The depression persists, functioning at work and home becomes harder, and in some cases acute suicidal thoughts emerge despite consistent medication adherence.
Spravato works through a fundamentally different mechanism than oral antidepressants. As an NMDA receptor antagonist, esketamine rapidly modulates glutamate signaling, the brain's primary excitatory neurotransmitter system. This can produce noticeable mood improvement within hours to days rather than the 4-8 weeks typical of SSRIs. Combined with an oral antidepressant and delivered in our certified clinic, Spravato offers a new option when other treatments have not worked, with patients monitored closely for safety throughout every session.
What Is Spravato?
The Science of NMDA Modulation
Spravato is the brand name for esketamine, an FDA-approved nasal spray used to treat adults with treatment-resistant depression (approved 2019) and major depressive disorder with acute suicidal ideation or behavior (approved 2020). It is the S-enantiomer of ketamine and is administered only alongside a newly prescribed oral antidepressant. According to the FDA approval for esketamine, Spravato is dispensed exclusively through certified healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS) program.
How Spravato Works
Spravato targets the N-methyl-D-aspartate (NMDA) receptor, a glutamate receptor involved in synaptic plasticity and mood regulation. By briefly blocking NMDA activity, esketamine triggers a cascade that increases brain-derived neurotrophic factor (BDNF) and promotes rapid synaptic repair in regions affected by chronic depression. Phase 3 trials (Popova 2019) reported a significantly greater reduction in depressive symptoms compared with placebo plus oral antidepressant as early as 24 hours after the first dose.
What Happens During Spravato Treatment
You self-administer the nasal spray under clinical supervision in our Pembroke Pines office. After dosing, you relax in a private, calming treatment suite while our team monitors blood pressure, sedation, and any dissociative effects for a full two hours before discharge.
Spravato Results and Duration
Most patients begin noticing mood improvement within the first 1-2 weeks of the induction phase. Remission rates at four weeks range from 27 to 53 percent in clinical trials. Ongoing maintenance dosing, guided by your psychiatric evaluation and medication management plan, helps sustain response long-term.
Treatment Timeline
First Signs
Within 24 hours to 1 week
Full Effect
4 weeks (induction phase complete)
Treatment Time
2-hour in-clinic visit
Recovery
No driving for 24 hours post-dose
Benefits of Spravato Treatment
Rapid, Clinically Validated Relief
- 01
Rapid Onset
Mood improvement possible within 24 hours to 1 week of first dose
- 02
FDA Approved
Only FDA-approved esketamine therapy for TRD and MDD with suicidality
- 03
Outpatient Delivery
Self-administered nasal spray, no IV needles or infusions required
- 04
Novel Mechanism
Targets NMDA glutamate system when SSRIs and SNRIs have not worked
- 05
Supervised Safety
REMS-certified clinic with 2-hour post-dose monitoring every visit
- 06
Integrated Care
Paired with medication management and therapy under one roof
Spravato vs. Alternatives
Compare Your Options
| Treatment | Mechanism | Administration | Time to Effect | Session Length | Monitoring | Best For |
|---|---|---|---|---|---|---|
| Spravato | NMDA antagonist | Nasal spray in REMS clinic | Hours to 1 week | 2 hours in clinic | 2-hour post-dose | Treatment-resistant depression |
| TMS Therapy | Magnetic brain stimulation | Outpatient, no medication | 2-4 weeks | 20-40 minutes | None required | TRD, non-medication option |
| Oral Antidepressants | Serotonin or norepinephrine reuptake | Daily oral pill at home | 4-8 weeks | Minutes at home | Routine office visits | First-line depression care |
| IV Ketamine | NMDA antagonist, racemic | Intravenous infusion off-label | Hours to days | 40-60 minutes | Varies by clinic | Off-label TRD (not offered here) |
Who Is a Good Candidate for Spravato?
Finding Your Best Treatment Fit
Spravato is specifically indicated for adults whose depression has not responded adequately to conventional oral antidepressants. According to guidance from the National Institute of Mental Health, roughly a third of patients with major depressive disorder experience treatment-resistant symptoms and may benefit from novel mechanisms.
Ideal Candidates for Spravato
- Adults age 18 or older with a confirmed diagnosis of major depressive disorder
- Patients who have tried two or more oral antidepressants at adequate dose and duration without relief
- Adults with major depressive disorder and acute suicidal ideation or behavior
- Patients willing to commit to twice-weekly induction visits and 2-hour monitoring
- Those who can arrange a ride home and avoid driving for 24 hours post-dose
- Patients seeking integrated care with psychiatric evaluation and medication management alongside Spravato
Who Should Wait or Avoid Spravato
- Patients with aneurysmal vascular disease, arteriovenous malformation, or history of intracerebral hemorrhage
- Anyone with known hypersensitivity to esketamine or ketamine
- Patients with uncontrolled hypertension or unstable cardiovascular disease
- Pregnant or breastfeeding individuals (Spravato is contraindicated)
- Patients with active substance use disorders involving dissociatives or hallucinogens
If you are unsure whether Spravato is right for you, consider discussing alternatives like TMS therapy, another FDA-approved option for treatment-resistant depression. Our team will review your full history and recommend the safest, most effective path.
What Happens During Spravato Treatment
REMS Authorization
Our team coordinates insurance approval and REMS enrollment with the Spravato registry.
In-Clinic Administration
You self-administer the nasal spray under supervision in a private treatment suite.
Post-Dose Monitoring
Our clinicians monitor blood pressure, sedation, and dissociation for a full 2 hours.
Ongoing Care
We adjust dosing frequency and integrate therapy and medication management for maintenance.
Risks and Side Effects
What to Know
Common Spravato Side Effects
The most frequently reported effects during or after treatment include dissociation (feeling detached from surroundings), mild sedation or drowsiness, dizziness, nausea, transient blood pressure elevation, vertigo, and headache. These typically peak within 40 minutes of dosing and resolve during the 2-hour monitoring period.
Rare Complications
Less common but serious risks include significant hypertensive episodes, respiratory depression, and rare reports of bladder irritation with repeated high-dose ketamine-class exposure. Abuse and dependence are also cited as boxed warnings, which is why Spravato is distributed exclusively under the REMS program.
Spravato Safety and REMS Status
Spravato received FDA approval in 2019 for treatment-resistant depression and in 2020 for MDD with acute suicidal ideation. The Spravato prescribing information requires every dose to be administered in a certified healthcare setting with post-dose monitoring. All six of Dr. Carmona's clinicians complete ongoing REMS training to minimize risk and intervene immediately if adverse events occur.
Spravato Cost in Pembroke Pines
Pricing and Payment Options
Spravato session costs in the Broward County market typically range from $600 to $900 per treatment before insurance, depending on dose (56 mg or 84 mg) and whether you are in the induction or maintenance phase. Most major commercial insurance plans and Medicare cover Spravato when medical necessity criteria are met, since it is FDA-approved. Exact out-of-pocket pricing will be discussed during your consultation based on your plan, dose, and frequency.
Insurance and Manufacturer Support
- Janssen CarePath (Spravato manufacturer) offers a copay savings program and benefits investigation for eligible commercially insured patients
- Medicare Part B typically covers Spravato administered in a certified clinic setting
- Commercial insurance requires prior authorization; our billing team handles the REMS paperwork and payer coordination
Flexible Payment Options
For patients with coverage gaps or high deductibles, we offer financial discussion at consultation:
- Self-pay rates with transparent per-session pricing discussed upfront
- Payment plans may be available for extended maintenance treatment courses
Why Choose R&C Psychiatry for Spravato in Pembroke Pines, FL
Pembroke Pines Trusted Provider
Certified Spravato Providers
All six R&C clinicians are fully Spravato and REMS trained
REMS-Compliant Clinic
Dedicated treatment suites with full post-dose monitoring equipment
Integrated Care Model
Spravato, medication management, and therapy delivered under one roof
Bilingual English and Spanish
Culturally attuned care for South Florida's diverse community
Explore More
Related Services
Advanced Treatments
Psychiatric Care
Frequently Asked Questions About Spravato
Your Questions Answered
01 What is Spravato?
Spravato (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression and major depressive disorder with acute suicidal ideation. It is always prescribed alongside a new oral antidepressant and delivered in a REMS-certified clinic.
02 How does Spravato work?
Spravato blocks NMDA receptors, modulating the glutamate system rather than serotonin. This stimulates rapid synaptic repair and BDNF release, producing mood improvement far faster than SSRIs, which act on serotonin and take 4 to 8 weeks.
03 Is Spravato covered by insurance?
Most commercial insurance plans and Medicare cover Spravato when medical necessity is documented, since it is FDA-approved. R&C Psychiatry's billing team handles prior authorization and REMS paperwork. Janssen CarePath also offers copay assistance for eligible commercial plans.
04 How is Spravato different from ketamine?
Spravato is the purified S-enantiomer of ketamine, delivered as a nasal spray with FDA approval and REMS oversight. IV ketamine is the racemic form used off-label. R&C offers Spravato only, and we can also discuss TMS therapy if you prefer a non-medication option.
05 What does Spravato treatment feel like?
Most patients describe mild dissociation, a floating or detached sensation, within 20 to 40 minutes of dosing. Drowsiness, dizziness, and slight blood pressure elevation are common. These effects resolve during the 2-hour monitored observation before you go home.
06 Does Spravato work?
Phase 3 trials (Popova 2019, Fedgchin 2019) showed Spravato combined with a new oral antidepressant significantly reduced depression scores within 24 hours to 4 weeks compared with placebo plus antidepressant. Remission rates at 4 weeks ranged from 27 to 53 percent.
07 How long does Spravato take to work?
Many patients notice improvement within the first 24 hours to 1 week of induction dosing, with peak response typically reached by week 4. Maintenance sessions every 1 to 2 weeks help sustain response long-term under Dr. Carmona's supervision.
Location9050 Pines Blvd, Suite 150
Pembroke Pines, FL, 33024
Pembroke Pines, FL, 33024
Phone(954) 872-0555
Schedule Your Spravato (Esketamine) Consultation
References
- PubMed (PMID: 29208217) - Daly EJ et al. (2018) demonstrated efficacy and dose response of intranasal esketamine in treatment-resistant depression over a double-blind, doubly randomized, placebo-controlled study.
- PubMed (PMID: 31180727) - Popova V et al. (2019) Phase 3 TRANSFORM-2 trial showed esketamine nasal spray plus oral antidepressant significantly reduced depressive symptoms in TRD.
- PubMed (PMID: 31166391) - Fedgchin M et al. (2019) Phase 3 TRANSFORM-1 trial evaluated fixed-dose esketamine plus oral antidepressant in TRD patients.
- FDA - FDA approved Spravato (esketamine) nasal spray for treatment-resistant depression in March 2019, available only through a restricted REMS program.
- National Institute of Mental Health - Overview of major depressive disorder, treatment resistance, and novel therapeutics including esketamine.